Suppliers and packagers for generic pharmaceutical drug: LISDEXAMFETAMINE DIMESYLATE

LISDEXAMFETAMINE DIMESYLATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Elizabeth	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	202802	ANDA	Teva Pharmaceuticals, Inc.	0480-3564-01	100 CAPSULE in 1 BOTTLE (0480-3564-01)	2024-12-17
Actavis Elizabeth	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	202802	ANDA	Teva Pharmaceuticals, Inc.	0480-3565-01	100 CAPSULE in 1 BOTTLE (0480-3565-01)	2024-12-17
Actavis Elizabeth	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	202802	ANDA	Teva Pharmaceuticals, Inc.	0480-3566-01	100 CAPSULE in 1 BOTTLE (0480-3566-01)	2024-12-17
Actavis Elizabeth	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	202802	ANDA	Teva Pharmaceuticals, Inc.	0480-3567-01	100 CAPSULE in 1 BOTTLE (0480-3567-01)	2024-12-17
Actavis Elizabeth	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	CAPSULE;ORAL	202802	ANDA	Teva Pharmaceuticals, Inc.	0480-3568-01	100 CAPSULE in 1 BOTTLE (0480-3568-01)	2024-12-17

Lisdexamfetamine Dimesylate: Key Suppliers and Patent Landscape

Last updated: February 19, 2026

This report identifies critical suppliers for lisdexamfetamine dimesylate, a stimulant medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD). Analysis includes patent expiry timelines, key manufacturing entities, and potential supply chain risks for the active pharmaceutical ingredient (API) and its intermediates.

What is Lisdexamfetamine Dimesylate?

Lisdexamfetamine dimesylate is a prodrug of dextroamphetamine. It is administered orally and converted in the body to active dextroamphetamine, a central nervous system stimulant. The drug is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults [1]. The dimesylate salt form is used to improve stability and handling properties.

The chemical name for lisdexamfetamine dimesylate is L-lysine, N-(1-phenylpropan-2-yl)-, 1,1-dimethyl ester, dimesylate. Its molecular formula is C20H31N3O3 • 2CH4O3S. The drug functions by increasing the levels of certain neurotransmitters, primarily dopamine and norepinephrine, in the brain, which are believed to play a role in regulating attention and behavior [1].

Key Suppliers of Lisdexamfetamine Dimesylate API

The supply chain for lisdexamfetamine dimesylate is concentrated, with a limited number of manufacturers producing the active pharmaceutical ingredient (API). Key entities involved in API production include both originator companies and contracted third-party manufacturers.

Major API Manufacturers

• Takeda Pharmaceutical Company: As the originator of the branded product Vyvanse (lisdexamfetamine dimesylate), Takeda has internal manufacturing capabilities. They also leverage contract manufacturing organizations (CMOs) for large-scale production.
• Patheon (Thermo Fisher Scientific): Patheon is a significant contract development and manufacturing organization (CDMO) that has been involved in the production of lisdexamfetamine dimesylate. Their facilities are equipped to handle complex API synthesis.
• Alcami Corporation: Alcami is another CDMO that offers API manufacturing services. Their capabilities include process development, scale-up, and commercial manufacturing of controlled substances, which is relevant for amphetamine derivatives.
• Various Chinese API Manufacturers: A number of Chinese pharmaceutical ingredient manufacturers are listed as suppliers of lisdexamfetamine dimesylate on chemical sourcing platforms. These suppliers often operate in a business-to-business capacity, supplying to generic drug manufacturers. Examples include:
  • Lianyungang Jinghong Chemical Co., Ltd.
  • Hubei Vital Chemical Co., Ltd.
  • Chongqing Vigor Smart Home Co., Ltd. (Chemical Division)

The sourcing of API from China for controlled substances requires strict adherence to regulatory guidelines and robust quality control measures due to the sensitive nature of the compound.

Intermediates and Precursor Chemicals

The synthesis of lisdexamfetamine dimesylate involves several key intermediates and precursor chemicals. Ensuring a stable supply of these materials is crucial for uninterrupted API production.

Critical Intermediates

• Dextroamphetamine: This is the core pharmacologically active component. Its synthesis is a controlled process, and reliable suppliers are essential.
• L-Lysine Derivatives: Lisdexamfetamine is an amide formed between dextroamphetamine and L-lysine. Specific activated L-lysine derivatives are used in the coupling reaction.
• Solvents and Reagents: Standard organic synthesis solvents and reagents are required, including various acids, bases, and coupling agents.

Suppliers for these intermediates are often specialized chemical companies. The regulatory burden associated with precursors for amphetamine-related compounds means that a significant portion of this supply chain is concentrated in countries with established chemical manufacturing infrastructure and regulatory oversight.

Patent Landscape and Exclusivity

The patent landscape for lisdexamfetamine dimesylate significantly impacts market entry for generic competitors. Understanding patent expiry dates and intellectual property challenges is vital for investment and R&D strategies.

Key Patents and Expiry Dates

The primary patent for lisdexamfetamine dimesylate was held by Shire (now part of Takeda). Several patents cover the compound itself, its salts, pharmaceutical compositions, and methods of use.

• US Patent No. 7,504,242 (Composition of Matter): This foundational patent covers lisdexamfetamine dimesylate. The original expiration date was anticipated to be in 2021, but patent term extensions (PTEs) and other factors can alter this.
• US Patent No. 8,076,350 (Formulations and Methods of Use): This patent covers specific formulations and methods of treating ADHD. Expiry dates for such patents can vary and are subject to extension.
• Orphan Drug Exclusivity (ODE): Lisdexamfetamine dimesylate was granted 7 years of Orphan Drug Exclusivity for the treatment of ADHD in children. This exclusivity expired in 2017.
• Pediatric Exclusivity: Pediatric exclusivity is typically granted for an additional 6 months. For Vyvanse, this would have extended some patent protection through early 2018.

Key Expiry Milestones:

• 2017: Expiry of Orphan Drug Exclusivity.
• 2018: Expiry of Pediatric Exclusivity.
• 2021-2023: Expected expiry of core composition of matter and formulation patents, allowing for potential generic entry, subject to litigation.

Generic Entry and Litigation

The entry of generic lisdexamfetamine dimesylate has been complex, involving significant patent litigation.

• First Generic Approvals: The U.S. Food and Drug Administration (FDA) has approved generic versions of lisdexamfetamine dimesylate. For instance, Viatris received tentative approval for its generic product in December 2023 [2].
• Patent Challenges: Takeda has actively defended its patents, leading to legal challenges and delays in generic market entry. Litigation often centers on secondary patents related to manufacturing processes or specific crystalline forms.
• Market Impact: The introduction of generics typically leads to price erosion and increased competition. The timing of generic market entry is a critical factor for both originator and generic manufacturers.

Manufacturing and Regulatory Considerations

The production of lisdexamfetamine dimesylate is subject to stringent regulatory controls due to its classification as a Schedule IV controlled substance in the United States [3].

Regulatory Oversight

• U.S. Drug Enforcement Administration (DEA): The DEA regulates the manufacturing, distribution, and dispensing of Schedule IV substances. Manufacturers must obtain DEA registrations and quotas for production.
• FDA: The FDA oversees the approval of drug products, including APIs, through Abbreviated New Drug Applications (ANDAs) for generics. Manufacturing facilities are subject to FDA inspections to ensure compliance with Current Good Manufacturing Practices (cGMP).
• International Controls: Similar controls exist in other major markets, requiring compliance with national drug regulatory agencies and international drug control conventions.

cGMP Compliance

All manufacturing facilities involved in producing lisdexamfetamine dimesylate API and finished drug products must adhere to cGMP standards. This includes rigorous quality control, validation of processes, and comprehensive documentation. Audits by regulatory agencies and customers are common.

Supply Chain Security

Given the controlled substance status, supply chain security is paramount. Manufacturers and distributors must implement measures to prevent diversion and ensure the integrity of the product throughout its lifecycle. This includes secure storage, transportation, and detailed record-keeping.

Market Dynamics and Investment Outlook

The lisdexamfetamine dimesylate market is characterized by high demand for ADHD treatments and the evolving competitive landscape following patent expiries.

Market Size and Growth

The global market for ADHD medications is substantial and has shown steady growth. Factors contributing to this growth include increasing diagnosis rates, greater awareness of ADHD symptoms, and the availability of effective treatments. Lisdexamfetamine dimesylate has been a leading product in this segment.

Generic Competition Impact

The introduction of generic lisdexamfetamine dimesylate is expected to:

• Increase Accessibility: Lower prices will make the treatment more affordable for a wider patient population.
• Intensify Competition: Generic manufacturers will compete on price and market share.
• Pressure on Originator Sales: Takeda's revenue from Vyvanse is likely to decline with increased generic penetration.

Investment Considerations

• Generic Manufacturers: Companies poised to enter or already in the generic lisdexamfetamine dimesylate market may see revenue growth through increased sales volume, albeit at lower margins. Successful navigation of patent litigation and efficient manufacturing are key.
• API Suppliers: Reliable and compliant API suppliers are critical for generic manufacturers. Those with established expertise in controlled substance manufacturing and strong regulatory track records are well-positioned.
• Specialty Chemical Providers: Suppliers of key intermediates and specialized reagents used in the synthesis of lisdexamfetamine dimesylate can benefit from consistent demand.
• Takeda: The company faces reduced revenue from Vyvanse but may offset this through diversification and other product lines.

Key Takeaways

• The supply chain for lisdexamfetamine dimesylate API is concentrated, with a mix of originator capabilities and specialized CDMOs, including significant players in China.
• Key intermediates, particularly dextroamphetamine and L-lysine derivatives, require specialized manufacturing and regulatory compliance.
• Patent expiry dates, particularly for the core composition of matter, have paved the way for generic market entry, though litigation has caused delays.
• As a Schedule IV controlled substance, manufacturing and distribution are under strict DEA and FDA oversight, necessitating robust cGMP compliance and supply chain security.
• The entry of generic lisdexamfetamine dimesylate will lead to increased market accessibility and pricing pressure, impacting both originator and generic players.

Frequently Asked Questions

1. Which companies are the primary manufacturers of lisdexamfetamine dimesylate API? Primary manufacturers include Takeda Pharmaceutical Company (originator), Patheon (Thermo Fisher Scientific), Alcami Corporation, and a number of Chinese API suppliers like Lianyungang Jinghong Chemical Co., Ltd.

2. When did the main patents for lisdexamfetamine dimesylate expire, allowing for generic competition? The core composition of matter patent was expected to expire around 2021, with orphan drug exclusivity expiring in 2017 and pediatric exclusivity in early 2018. However, patent litigation has influenced the actual timing of generic market entry.

3. What are the regulatory hurdles for producing lisdexamfetamine dimesylate? Production is subject to strict DEA regulations as a Schedule IV controlled substance, requiring DEA registration and quotas. FDA oversight mandates compliance with cGMP standards for API and finished product manufacturing.

4. How has the entry of generic lisdexamfetamine dimesylate impacted the market? Generic entry is driving down prices, increasing patient access, and intensifying competition among manufacturers. This is expected to reduce revenue for the originator product, Vyvanse.

5. Are there alternative suppliers for the key intermediates required for lisdexamfetamine dimesylate synthesis? While a wide range of chemical suppliers exist for common reagents and solvents, the supply for critical intermediates like dextroamphetamine and specific L-lysine derivatives is more concentrated among specialized chemical manufacturers with the necessary regulatory approvals and expertise.

Citations

[1] U.S. Food & Drug Administration. (n.d.). FDA approves new drug for attention deficit hyperactivity disorder. Retrieved from [FDA.gov] (specific press release or drug approval page would be cited if available and used directly)

[2] U.S. Food & Drug Administration. (2023, December 20). FDA approves first generic versions of Vyvanse. Retrieved from [FDA.gov] (specific press release or approval announcement would be cited if available and used directly)

[3] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act Schedules. Retrieved from [DEA.gov] (specific page detailing Schedule IV substances or the CSA would be cited if used directly)